Literature DB >> 8311844

Mechanism of action of acyclic nucleoside phosphonates against herpes virus replication.

J Neyts1, E De Clercq.   

Abstract

Foremost among the acyclic nucleoside phosphonates currently pursued for their potential in the treatment of herpes and retrovirus infections are (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA). These compounds are as such taken up by the cells and then phosphorylated by cellular enzymes to their diphosphoryl derivatives HPMPCpp and PMEApp. The main target for the antiviral action of HPMPCpp and PMEApp is the viral DNA polymerase. Whereas PMEApp has been shown to interact as a DNA chain terminator with both retro- and herpes viruses, the mechanism by which HPMPCpp inhibits herpes viral DNA synthesis remains the subject of further study.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8311844     DOI: 10.1016/0006-2952(94)90435-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

1.  Disposition of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine.

Authors:  M K Bijsterbosch; L J Smeijsters; T J van Berkel
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 2.  Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS.

Authors:  G L Plosker; S Noble
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 3.  Acyclic nucleosides as antiviral compounds.

Authors:  S Freeman; J M Gardiner
Journal:  Mol Biotechnol       Date:  1996-04       Impact factor: 2.695

Review 4.  Bioactive Natural Antivirals: An Updated Review of the Available Plants and Isolated Molecules.

Authors:  Syam Mohan; Manal Mohamed Elhassan Taha; Hafiz A Makeen; Hassan A Alhazmi; Mohammed Al Bratty; Shahnaz Sultana; Waquar Ahsan; Asim Najmi; Asaad Khalid
Journal:  Molecules       Date:  2020-10-22       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.